logo
  

Allianz Q4 Profit Declines - Quick Facts

German insurer Allianz (AZSEY.PK) reported that its fourth-quarter net income attributable to shareholders declined to 1.22 billion euros from 1.26 billion euros in the same quarter last year. Earnings per share were 2.67 euros, down from 2.72 euros in the prior year period.

Operating profit for the latest fourth quarter was 2.26 billion euros, down from 2.38 billion euros in the previous year.

Quarterly total revenues were 30.1 billion euros, compared with 26.8 billion euros in the comparable quarter last year.

The clarification of capital requirements under the new regulation Solvency II allowed a redefinition of the Allianz SE dividend policy. In November 2014, the Management Board and the Supervisory Board passed the new policy.

Starting with fiscal year 2014, 50 percent of net income attributable to shareholders will be paid out, compared to 40 percent previously. Following the new policy, the Management Board has proposed to the Supervisory Board
of Allianz SE a dividend of 6.85 euros per share, an increase of 29 percent compared to the previous year.

"The revised dividend policy reflects our successful efforts to prepare Allianz for the future," said Michael Diekmann. "We expect the economic environment to remain challenging in 2015. Our current operating profit
outlook for 2015 is 10.4 billion euros, plus/minus 400 million euros."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT